[300+ Pages Report] The global demand for the cancer gene therapy is expected to increase at a 10.1%CAGRfrom 2022 to 2032, reaching US$ 2 Billion in 2022. As per Future Market Insights (FMI), the oncolytic virotherapy segment held 49.3% of the overall global cancer gene therapy market in 2021, which is projected to be valued at US$ 5.3 Billion in the year 2032.
Data Points
Market Insights
Cancer Gene Therapy Market Base Year Value (2021)
US$ 1.9 Billion
Estimated Market Size (2022)
US$ 2.0 Billion
Projected Market Valuation (2032)
US$ 5.3 Billion
Value-based CAGR (2022 to 2032)
10.1%
Market Share of Top 5 Countries
74.8%
The global market of cancer gene therapy accounted for nearly 45.2% of the overall global gene therapy market worth around US$4.0 Billion in 2021.
Initially, gene therapy for monogenetic illnesses was popular; however, gene therapy for cancer treatment is growing in popularity. Cancer gene therapy is a method of treating cancer patients by introducing therapeutic DNA into their bodies.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
2017-2021 Cancer Gene Therapy Market Historic Outlook Vs 2022-2032 Forecast
Demand for cancer gene therapy is forecast to increase at a 10.1% CAGR over the forecast period, in comparison to the 7.1% CAGR registered between 2017 to 2021.
Multiple mutations in a single cell cause cancer to spread. Cancer cells infiltrate new cell, have a rapid metabolism, and are constantly altering shape. Surgery, radiation therapy, and chemotherapy are options for cancer treatment. Gene therapy is utilised if the abovementioned treatments do not deliver the intended results.
In gene therapy, a functional gene, also known as therapeutic DNA, is inserted into the cells of a cancer patient to modify metabolism, alter or repair acquired genetic abnormalities, and impart new functions to cells.
For the last two decades, gene therapy has been a hot topic of research. Ten gene therapy products have been authorized for marketing in at least one country as of January 28, 2018. According to recent forecasts, 12 to 14 new gene therapies will be filed for approval in the following few years, with roughly 40 new medicines approved by the end of 2022.
Oncolytic viral therapy, gene transfer, and gene-induced immunotherapy are examples of cancer treatments. Gene therapy can be used in a variety of ways. For instance, replacing missing or defective genes with healthy genes, altering gene regulation, or introducing foreign genes into cells to alter their function or survival.
Electroporation, magnetofection, naked / plasmid vectors, sonoporation, and gene guns are examples of transgene treatment. Gene-induced immunotherapy is projected to dominate the global cancer gene therapy market over the forecast period.
Various organizations are investing heavily in cancer research. For Instance, in October 2017, American Cancer Society (ACS) approved a US$ 39.8 million funding for 78 training and research grants. These grants were awarded to researchers at 57 institutions across the U.S.
This has brought about significant developments in the field of cancer research and has led to further growth in the global oncogene therapy market.
Governments in various underdeveloped nations are actively taking steps to stimulate various research efforts aimed at producing cancer gene therapy and treatment plans to lower mortality and morbidity rates, which will drive the market.
Because of its high success rate in preclinical and clinical trials, cancer gene therapy is gaining prominence. The most popular method of cancer gene therapy is to replace a cancer-causing mutant gene with a healthy copy of the gene.
What Are The Key Opportunities For Cancer Gene Therapy Market Players?
Rising success rates of novel medicines and ethical acceptability of gene therapy for cancer treatment will create lucrative opportunities for cancer gene therapy market players. For instance, in August 2017, the US Food and Drug Administration (USFDA) approved an innovative treatment for children suffering from acute lymphoblastic leukemia. This gene therapy, “tisagenlecleucel (Kymriah™)”, is the first to be approved for cancer by the USFDA.
Gene therapy is one of the conceivable treatments suitable to the senior population with low to intermediate risk, according to respondents. In the U.S., cancer gene therapy is widely accepted. As a result, experts have emphasized that cancer gene therapy is deemed safe in the older population, and that the danger associated with gene therapy is minimal.
Find your sweet spots for generating winning opportunities in this market.
Which Factors Are Restraining The Demand For Cancer Gene Therapy?
The high costs associated with gene therapy, along with a detrimental immune response are expected to impede the growth in the cancer gene therapy market during the forecast period.
The availability of other cancer treatment types such as chemotherapy and surgery is expected to limit sales. Viruses are the most efficient biological vectors for delivering genes to target cells. Due to safety concerns, non-viral vector delivery systems could be used as a safer alternative.
The shortage of qualified medical professionals for cancer gene therapy in developing countries can hinder the growth of the global cancer gene therapy market.
According to government data and Indian medical association, less than 1,600 oncologists are treating an estimated 1 million cancer patients in the country, with a 20% increase in cancer cases by the end of the decade.
Country-wise Insights
What is the U.S. Cancer Gene Therapy Market Outlook?
“Rising Awareness Regarding DNA Therapy for Cancer in the U.S. Will Augment Growth”
The U.S. dominated the North America cancer gene therapy market, holding 96.8% of the total market share in 2021, and the trend is expected to continue over the assessment period.
Breast cancer is one of the most frequent diseases in women worldwide, according to the Centers for Disease Control and Prevention (CDC), and it remains the second-largest cause of cancer death in women worldwide, fuelling the expansion of the cancer gene therapy industry. With a high prevalence of cancer in the country, the U.S. market is set to expand at a lucrative rate throughout assessment period.
Why is the China Cancer Gene Therapy Market Considered Lucrative?
“Increasing Adoption of Genetic Mutation Lung Cancer Treatment in China Will Boost Sales”
Sales in China are set to account for 32.3% of the East Asia cancer gene therapy market by 2032. The 'Regulations on the Management of Clinical Application of New Biomedical Technologies' and 'Regulations on the Safety Management of Biotechnology Research and Development' have been drafted by China's national health, scientific, and technology agencies.
The purpose of improving the rules and regulations is to create a more reasonable supervisory mechanism, strengthen supervision, increase legal responsibility, and encourage healthy development of biotechnology research, applications, and related businesses. Such developments are expected to bode well for the market over the forecast period.
What is Driving the Germany Cancer Gene Therapy Market?
“Increasing Demand for Gene Targeted Chemotherapy in Germany Will Steer Sales”
Demand in Germany is projected to increase at a CAGR of 11.9% during the forecast period. Manufacturers, healthcare professionals, and patients are hopeful as regulators create a defined path for speedy access to novel cancer gene therapies.
Players, on the other hand, are analysing the new medicines' added benefits. In the realm of gene treatments, major advancements are expected in the forthcoming years, thereby fueling sales in Germany.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category-Wise Insights
Which Cancer Gene Therapy is Driving the Market?
“Demand for Oncolytic Virotherapy Will Gain Traction”
Based on therapy, the oncolytic virotherapy accounted for about 49.3% of the total market share in 2021. Sales in this segment are expected to increase at a 9.5% CAGR over the forecast period.
Oncolytic virus therapy is a promising new therapeutic approach for cancer treatment that has recently been identified. An oncolytic virus is a genetically designed or naturally occurring virus that may selectively reproduce in cancer cells and kill them while causing no harm to normal tissues. Oncolytic virus therapy differs from gene therapy in that it exploits the virus as an active pharmacological reagent rather than just a carrier for transgene delivery.
Which Indication Category is Leading the Cancer Gene Therapy Market?
“Sales of Cancer Gene Therapy for Breast Cancer to Remain High”
In terms of indication, the breast cancer segment held about 24.5% of the total market share in 2021, and is expected to expand at a 9.7%CAGR over the forecast period. Various governments in underdeveloped nations are taking steps to stimulate research efforts aimed at producing cancer gene therapy and treatment plans to lower mortality and morbidity rates, which will drive growth in the cancer gene therapy market over the forecast period.
Which Service Provider Benefits the Most in the Cancer Gene Therapy Market?
“Adoption of Cancer Gene Therapy in Hospitals Will Increase”
By service provider, the hospitals segment will expand at a 9.3% CAGR over the assessment period. The presence of trained providers, as well as institutional facilities equipped with treatment options are some factors expected to drive sales in this segment in the forthcoming years.
Moreover, the availability of reimbursement plans for gene therapy will continue pushing sales over the forecast period.
Competitive Landscape
Leading cancer gene therapy manufacturers are focusing on technological advancements in order to increase revenue and expand their footprint in emerging markets through acquisitions, partnerships, and collaborations.
For instance:
In Sept 2021, Adaptimmune partnered with Genentech to develop allogeneic cell therapies indicated for multiple cancers.
In June 2021, Eisai and Bristol Myers Squibb agreed to collaborate on the development and commercialization of Eisai's ADC, MORAb-202, for advanced solid malignancies.
In June 2021, GSK and iTeos Therapeutics collaborated to develop EOS-448, an anti-TIGIT monoclonal antibody that had previously been approved in phase 1 for advanced solid malignancies.
Report Scope
Attributes
Details
Estimated Market Size (2022)
US$ 2 Billion
Projected Market Valuation (2032)
US$ 5.3 Billion
Value-based CAGR (2022 to 2032)
10.1%
Forecast Period
2022 to 2032
Historical Data Available for
2017 to 2021
Market Analysis
US$ Billion for Value
Key Regions Covered
North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa
Key Countries Covered
The USA, Canada, Brazil, Mexico, Argentina, Germany, The UK, France, Italy, Spain, Russia, Poland, Georgia China, Japan, South Korea, India, Thailand, Indonesia, Malaysia, Australia, New Zealand, GCC Countries, Turkey, and South Africa
Key Market Segments Covered
Therapy, Indication, Service Provider, and Region
Key Companies Profiled
Merck KGaA
Novartis AG
AstraZeneca Plc.
BIOCAD
Crinetics Pharmaceuticals, Inc.
EffRx Pharmaceuticals S.A.
Euroscreen S.A.
Vicore Pharma AB
Amgen
Bristol-Myers Squibb
Cell Genesys Inc.
Adaptimmune Therapeutics plc.
Achieve Life Science Inc.
BioCanCell Ltd.
Genelux Corporation
Advantagene Inc.,
GenVec Inc.
GlaxoSmithKline PLC
Amgen Inc.
Key Market Segments Covered in Cancer Gene Therapy Industry Research
By Therapy:
Gene Induced Immunotherapy
Oncolytic Virotherapy
Gene Transfer
Others
By Indication:
Breast Cancer
Ovarian Cancer
Liver Cancer
Pancreatic Cancer
Lung Cancer
Prostate Cancer
By Service Provider:
Hospitals
Clinical Research Laboratory
Oncology institutes
By Region:
North America
Latin America
Europe
South Asia
East Asia
Oceania
The Middle East and Africa (MEA)
Frequently Asked Questions
How much is the cancer gene therapy market currently worth?
The global cancer gene therapy market is forecast to reach US$ 2 Bn in 2022 and is set to expand 2.6X over the forecast period.
What is the sales forecast for cancer gene therapy through 2032?
The cancer gene therapy market is expected to reach US$ 5.3 Bn by end of 2032 at a CAGR of 10.1%
What are the key trends shaping the cancer gene therapy market?
Key trends expected to drive sales in the market include increasing prevalence of cancer, rising awareness about healthcare practices among consumers, and an increase in the adoption of cancer gene therapy.
What are the restraints affecting the cancer gene therapy market?
The key restraints affecting the cancer gene therapy market are the presence of alternatives to cancer gene therapy, the high cost involved in cancer gene therapy, and the shortage of skilled professionals.
Which region has the highest market share in the global cancer gene therapy market?
North America held the highest market share of 52.8% by value in 2021 in the global cancer gene therapy market.
Which are the top 5 countries driving demand for cancer gene therapy?
The U.S., the U.K., Germany, France, and Japan are the top five countries that are expected to drive demand in the cancer gene therapy market.
Which are the key manufacturers of the cancer gene therapy market?
Merck KGaA, Novartis AG, AstraZeneca Plc. BIOCAD, Crinetics Pharmaceuticals, Inc., EffRx Pharmaceuticals S.A., Euroscreen S.A., Vicore Pharma AB, Amgen, Bristol-Myers Squibb, Cell Genesys Inc., Adaptimmune Therapeutics plc., Achieve Life Science Inc., BioCanCell Ltd., Genelux Corporation, Advantagene Inc., GenVec Inc., GlaxoSmithKline PLC, Amgen Inc. are the key manufacturers in this market.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Technology Roadmap
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Key Success Factors
4.1. Technology Assessment
4.2. Disease Epidemiology
4.3. Regulatory Landscape
4.4. Reimbursement Outlook
4.5. Key Marketing & Promotional Strategies Adopted By Companies
4.6. PESTLE Analysis
4.7. Porter’s Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Rise in Healthcare Spending
5.1.3. Global Expenditure on Healthcare Infrastructure
5.2. Forecast Factors - Relevance & Impact
5.2.1. Mergers and Acquisitions
5.2.2. Disease Prevalence and Growth
5.2.3. R&D for Cancer Gene Therapy
5.2.4. Technological Advancements
5.2.5. Regulatory Framework
5.2.6. Reimbursement Policies
5.2.7. Prevalence of Geriatric Age Group
5.2.8. Global Burden of Cancer
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. COVID-19 and Impact Analysis
6.1.1. Revenue By Therapy
6.1.2. Revenue By Indication
6.1.3. Revenue By Service Provider
6.1.4. Revenue By Country
6.2. 2021 Market Scenario
7. Global Market Demand (in Value or Size in US$ Bn) Analysis 2017–2021 and Forecast, 2022–2032
7.1. Historical Market Value (US$ Bn) Analysis, 2017–2021
7.2. Current and Future Market Value (US$ Bn) Projections, 2022–2032
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Market Analysis 2017–2021 and Forecast 2022–2032, By Therapy
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Bn) Trend Analysis, By Therapy, 2017–2021
8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, By Therapy, 2022–2032
8.3.1. Gene Induced Immunotherapy
8.3.2. Oncolytic Virotherapy
8.3.3. Gene Transfer
8.3.4. Others
8.4. Market Attractiveness Analysis By Therapy
9. Global Market Analysis 2017–2021 and Forecast 2022–2032, By Indication
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Bn) Trend Analysis, By Indication, 2017–2021
9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, By Indication, 2022–2032
9.3.1. Breast Cancer
9.3.2. Ovarian Cancer
9.3.3. Liver Cancer
9.3.4. Pancreatic Cancer
9.3.5. Lung Cancer
9.3.6. Prostate Cancer
9.4. Market Attractiveness Analysis By Indication
10. Global Market Analysis 2017–2021 and Forecast 2022–2032, By Service Provider
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Bn) Trend Analysis, By Service Provider, 2017–2021
10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, By Service Provider, 2022–2032
10.3.1. Hospitals
10.3.2. Clinical Research Laboratory
10.3.3. Oncology institutes
10.4. Market Attractiveness Analysis By Service Provider
11. Global Market Analysis 2017–2021 and Forecast 2022–2032, by Region
11.1. Introduction
11.2. Historical Market Size (US$ Bn) Analysis, By Region, 2017–2021
11.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Region, 2022–2032
11.3.1. North America
11.3.2. Latin America
11.3.3. Europe
11.3.4. East Asia
11.3.5. South Asia
11.3.6. Oceania
11.3.7. Middle East and Africa (MEA)
11.4. Market Attractiveness Analysis By Region
12. North America Market Analysis 2017–2021 and Forecast 2022–2032
12.1. Introduction
12.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2017–2021
12.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2022–2032
12.3.1. By Country
12.3.1.1. U.S.
12.3.1.2. Canada
12.3.2. By Therapy
12.3.3. By Indication
12.3.4. By Service Provider
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Therapy
12.4.3. By Indication
12.4.4. By Service Provider
12.5. Market Trends
12.6. Key Market Participants - Intensity Mapping
12.7. Drivers and Restraints - Impact Analysis
12.8. Country Level Analysis & Forecast
12.8.1. U.S. Market Analysis
12.8.1.1. Introduction
12.8.1.2. Market Analysis and Forecast by Market Taxonomy
12.8.1.2.1. By Therapy
12.8.1.2.2. By Indication
12.8.1.2.3. By Service Provider
12.8.2. Canada Market Analysis
12.8.2.1. Introduction
12.8.2.2. Market Analysis and Forecast by Market Taxonomy
12.8.2.2.1. By Therapy
12.8.2.2.2. By Indication
12.8.2.2.3. By Service Provider
13. Latin America Market Analysis 2017–2021 and Forecast 2022–2032
13.1. Introduction
13.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2017–2021
13.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2022–2032
13.3.1. By Country
13.3.1.1. Mexico
13.3.1.2. Brazil
13.3.1.3. Argentina
13.3.1.4. Rest of Latin America
13.3.2. By Therapy
13.3.3. By Indication
13.3.4. By Service Provider
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Therapy
13.4.3. By Indication
13.4.4. By Service Provider
13.5. Market Trends
13.6. Key Market Participants - Intensity Mapping
13.7. Drivers and Restraints - Impact Analysis
13.8. Country Level Analysis & Forecast
13.8.1. Mexico Market Analysis
13.8.1.1. Introduction
13.8.1.2. Market Analysis and Forecast by Market Taxonomy
13.8.1.2.1. By Therapy
13.8.1.2.2. By Indication
13.8.1.2.3. By Service Provider
13.8.2. Brazil Market Analysis
13.8.2.1. Introduction
13.8.2.2. Market Analysis and Forecast by Market Taxonomy
13.8.2.2.1. By Therapy
13.8.2.2.2. By Indication
13.8.2.2.3. By Service Provider
13.8.3. Argentina Market Analysis
13.8.3.1. Introduction
13.8.3.2. Market Analysis and Forecast by Market Taxonomy
13.8.3.2.1. By Therapy
13.8.3.2.2. By Indication
13.8.3.2.3. By Service Provider
14. Europe Market Analysis 2017–2021 and Forecast 2022–2032
14.1. Introduction
14.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2017–2021
14.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2022–2032
14.3.1. By Country
14.3.1.1. Germany
14.3.1.2. Italy
14.3.1.3. France
14.3.1.4. U.K.
14.3.1.5. Spain
14.3.1.6. BENELUX
14.3.1.7. Nordic Countries
14.3.1.8. Russia
14.3.1.9. Rest of Europe
14.3.2. By Therapy
14.3.3. By Indication
14.3.4. By Service Provider
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Therapy
14.4.3. By Indication
14.4.4. By Service Provider
14.5. Market Trends
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country Level Analysis & Forecast
14.8.1. Germany Market Analysis
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Therapy
14.8.1.2.2. By Indication
14.8.1.2.3. By Service Provider
14.8.2. Italy Market Analysis
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Therapy
14.8.2.2.2. By Indication
14.8.2.2.3. By Service Provider
14.8.3. France Market Analysis
14.8.3.1. Introduction
14.8.3.2. Market Analysis and Forecast by Market Taxonomy
14.8.3.2.1. By Therapy
14.8.3.2.2. By Indication
14.8.3.2.3. By Service Provider
14.8.4. U.K. Market Analysis
14.8.4.1. Introduction
14.8.4.2. Market Analysis and Forecast by Market Taxonomy
14.8.4.2.1. By Therapy
14.8.4.2.2. By Indication
14.8.4.2.3. By Service Provider
14.8.5. Spain Market Analysis
14.8.5.1. Introduction
14.8.5.2. Market Analysis and Forecast by Market Taxonomy
14.8.5.2.1. By Therapy
14.8.5.2.2. By Indication
14.8.5.2.3. By Service Provider
14.8.6. BENELUX Market Analysis
14.8.6.1. Introduction
14.8.6.2. Market Analysis and Forecast by Market Taxonomy
14.8.6.2.1. By Therapy
14.8.6.2.2. By Indication
14.8.6.2.3. By Service Provider
14.8.7. Nordic Countries Contact Lenses Market Analysis
14.8.7.1. Introduction
14.8.7.2. Market Analysis and Forecast by Market Taxonomy
14.8.7.2.1. By Therapy
14.8.7.2.2. By Indication
14.8.7.2.3. By Service Provider
14.8.8. Russia Market Analysis
14.8.8.1. Introduction
14.8.8.2. Market Analysis and Forecast by Market Taxonomy
14.8.8.2.1. By Therapy
14.8.8.2.2. By Indication
14.8.8.2.3. By Service Provider
15. East Asia Market Analysis 2017–2021 and Forecast 2022–2032
15.1. Introduction
15.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2017–2021
15.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2022–2032
15.3.1. By Country
15.3.1.1. China
15.3.1.2. Japan
15.3.1.3. South Korea
15.3.2. By Therapy
15.3.3. By Indication
15.3.4. By Service Provider
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Therapy
15.4.3. By Indication
15.4.4. By Service Provider
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
15.8.1. China Market Analysis
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Therapy
15.8.1.2.2. By Indication
15.8.1.2.3. By Service Provider
15.8.2. Japan Market Analysis
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. By Therapy
15.8.2.2.2. By Indication
15.8.2.2.3. By Service Provider
15.8.3. South Korea Market Analysis
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast by Market Taxonomy
15.8.3.2.1. By Therapy
15.8.3.2.2. By Indication
15.8.3.2.3. By Service Provider
16. South Asia Market Analysis 2017–2021 and Forecast 2022–2032
16.1. Introduction
16.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2017–2021
16.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2022–2032
16.3.1. By Country
16.3.1.1. India
16.3.1.2. Indonesia
16.3.1.3. Malaysia
16.3.1.4. Philippines
16.3.1.5. Thailand
16.3.1.6. Vietnam
16.3.1.7. Rest of South Asia
16.3.2. By Therapy
16.3.3. By Indication
16.3.4. By Service Provider
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Therapy
16.4.3. By Indication
16.4.4. By Service Provider
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
16.8.1. India Market Analysis
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Therapy
16.8.1.2.2. By Indication
16.8.1.2.3. By Service Provider
16.8.2. Indonesia Market Analysis
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Therapy
16.8.2.2.2. By Indication
16.8.2.2.3. By Service Provider
16.8.3. Malaysia Market Analysis
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast by Market Taxonomy
16.8.3.2.1. By Therapy
16.8.3.2.2. By Indication
16.8.3.2.3. By Service Provider
16.8.4. Philippines Market Analysis
16.8.4.1. Introduction
16.8.4.2. Market Analysis and Forecast by Market Taxonomy
16.8.4.2.1. By Therapy
16.8.4.2.2. By Indication
16.8.4.2.3. By Service Provider
16.8.5. Thailand Market Analysis
16.8.5.1. Introduction
16.8.5.2. Market Analysis and Forecast by Market Taxonomy
16.8.5.2.1. By Therapy
16.8.5.2.2. By Indication
16.8.5.2.3. By Service Provider
16.8.6. Vietnam Market Analysis
16.8.6.1. Introduction
16.8.6.2. Market Analysis and Forecast by Market Taxonomy
16.8.6.2.1. By Therapy
16.8.6.2.2. By Indication
16.8.6.2.3. By Service Provider
17. Oceania Market 2012-2021 and Forecast 2022-2032
17.1. Introduction
17.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2017–2021
17.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2022–2032
17.3.1. By Country
17.3.1.1. Australia
17.3.1.2. New Zealand
17.3.2. By Therapy
17.3.3. By Indication
17.3.4. By Service Provider
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Therapy
17.4.3. By Indication
17.4.4. By Service Provider
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis & Forecast
17.8.1. Australia Market Analysis
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Therapy
17.8.1.2.2. By Indication
17.8.1.2.3. By Service Provider
17.8.2. New Zealand Market Analysis
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Therapy
17.8.2.2.2. By Indication
17.8.2.2.3. By Service Provider
18. Middle East and Africa (MEA) Market Analysis 2017–2021 and Forecast 2022–2032
18.1. Introduction
18.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2017–2021
18.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2022–2032
18.3.1. By Country
18.3.1.1. GCC Countries
18.3.1.2. Israel
18.3.1.3. Turkey
18.3.1.4. South Africa
18.3.1.5. North Africa
18.3.1.6. Rest of Middle East and Africa
18.3.2. By Therapy
18.3.3. By Indication
18.3.4. By Service Provider
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Therapy
18.4.3. By Indication
18.4.4. By Service Provider
18.5. Market Trends
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country Level Analysis & Forecast
18.8.1. GCC Countries Market Analysis
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast by Market Taxonomy
18.8.1.2.1. By Therapy
18.8.1.2.2. By Indication
18.8.1.2.3. By Service Provider
18.8.2. Israel Market Analysis
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast by Market Taxonomy
18.8.2.2.1. By Therapy
18.8.2.2.2. By Indication
18.8.2.2.3. By Service Provider
18.8.3. Turkey Market Analysis
18.8.3.1. Introduction
18.8.3.2. Market Analysis and Forecast by Market Taxonomy
18.8.3.2.1. By Therapy
18.8.3.2.2. By Indication
18.8.3.2.3. By Service Provider
18.8.4. South Africa Market Analysis
18.8.4.1. Introduction
18.8.4.2. Market Analysis and Forecast by Market Taxonomy
18.8.4.2.1. By Therapy
18.8.4.2.2. By Indication
18.8.4.2.3. By Service Provider
18.8.5. North Africa Market Analysis
18.8.5.1. Introduction
18.8.5.2. Market Analysis and Forecast by Market Taxonomy
18.8.5.2.1. By Therapy
18.8.5.2.2. By Indication
18.8.5.2.3. By Service Provider
19. Market Structure Analysis
19.1. Market Analysis by Tier of Companies
19.2. Market Share Analysis of Top Players
19.3. Market Presence Analysis
20. Competition Analysis
20.1. Competition Dashboard
20.2. Competition Benchmarking
20.3. Competition Deep Dive
20.3.1. Merck KGaA
20.3.1.1. Overview
20.3.1.2. Product Portfolio
20.3.1.3. Profitability by Market Segments (Product/Channel/Region)
20.3.1.4. Sales Footprint
20.3.1.5. Key Financials
20.3.1.6. SWOT Analysis
20.3.1.7. Strategy Overview
20.3.2. Novartis AG
20.3.2.1. Overview
20.3.2.2. Product Portfolio
20.3.2.3. Profitability by Market Segments (Product/Channel/Region)
20.3.2.4. Sales Footprint
20.3.2.5. Key Financials
20.3.2.6. SWOT Analysis
20.3.2.7. Strategy Overview
20.3.3. AstraZeneca Plc
20.3.3.1. Overview
20.3.3.2. Product Portfolio
20.3.3.3. Profitability by Market Segments (Product/Channel/Region)
20.3.3.4. Sales Footprint
20.3.3.5. Key Financials
20.3.3.6. SWOT Analysis
20.3.3.7. Strategy Overview
20.3.4. BIOCAD
20.3.4.1. Overview
20.3.4.2. Product Portfolio
20.3.4.3. Profitability by Market Segments (Product/Channel/Region)
20.3.4.4. Sales Footprint
20.3.4.5. Key Financials
20.3.4.6. SWOT Analysis
20.3.4.7. Strategy Overview
20.3.5. Crinetics Pharmaceuticals, Inc.
20.3.5.1. Overview
20.3.5.2. Product Portfolio
20.3.5.3. Profitability by Market Segments (Product/Channel/Region)
20.3.5.4. Sales Footprint
20.3.5.5. Key Financials
20.3.5.6. SWOT Analysis
20.3.5.7. Strategy Overview
20.3.6. EffRx Pharmaceuticals S.A.
20.3.6.1. Overview
20.3.6.2. Product Portfolio
20.3.6.3. Profitability by Market Segments (Product/Channel/Region)
20.3.6.4. Sales Footprint
20.3.6.5. Key Financials
20.3.6.6. SWOT Analysis
20.3.6.7. Strategy Overview
20.3.7. Euroscreen S.A.
20.3.7.1. Overview
20.3.7.2. Product Portfolio
20.3.7.3. Profitability by Market Segments (Product/Channel/Region)
20.3.7.4. Sales Footprint
20.3.7.5. Key Financials
20.3.7.6. SWOT Analysis
20.3.7.7. Strategy Overview
20.3.8. Vicore Pharma AB
20.3.8.1. Overview
20.3.8.2. Product Portfolio
20.3.8.3. Profitability by Market Segments (Product/Channel/Region)
20.3.8.4. Sales Footprint
20.3.8.5. Key Financials
20.3.8.6. SWOT Analysis
20.3.8.7. Strategy Overview
20.3.9. Amgen
20.3.9.1. Overview
20.3.9.2. Product Portfolio
20.3.9.3. Profitability by Market Segments (Product/Channel/Region)
20.3.9.4. Sales Footprint
20.3.9.5. Key Financials
20.3.9.6. SWOT Analysis
20.3.9.7. Strategy Overview
20.3.10. Bristol-Myers Squibb
20.3.10.1. Overview
20.3.10.2. Product Portfolio
20.3.10.3. Profitability by Market Segments (Product/Channel/Region)
20.3.10.4. Sales Footprint
20.3.10.5. Key Financials
20.3.10.6. SWOT Analysis
20.3.10.7. Strategy Overview
20.3.11. Cell Genesys Inc.
20.3.11.1. Overview
20.3.11.2. Product Portfolio
20.3.11.3. Profitability by Market Segments (Product/Channel/Region)
20.3.11.4. Sales Footprint
20.3.11.5. Key Financials
20.3.11.6. SWOT Analysis
20.3.11.7. Strategy Overview
20.3.12. Adaptimmune Therapeutics plc
20.3.12.1. Overview
20.3.12.2. Product Portfolio
20.3.12.3. Profitability by Market Segments (Product/Channel/Region)
20.3.12.4. Sales Footprint
20.3.12.5. Key Financials
20.3.12.6. SWOT Analysis
20.3.12.7. Strategy Overview
20.3.13. Achieve Life Science Inc.
20.3.13.1. Overview
20.3.13.2. Product Portfolio
20.3.13.3. Profitability by Market Segments (Product/Channel/Region)
20.3.13.4. Sales Footprint
20.3.13.5. Key Financials
20.3.13.6. SWOT Analysis
20.3.13.7. Strategy Overview
20.3.14. BioCanCell Ltd.
20.3.14.1. Overview
20.3.14.2. Product Portfolio
20.3.14.3. Profitability by Market Segments (Product/Channel/Region)
20.3.14.4. Sales Footprint
20.3.14.5. Key Financials
20.3.14.6. SWOT Analysis
20.3.14.7. Strategy Overview
20.3.15. Genelux Corporation
20.3.15.1. Overview
20.3.15.2. Product Portfolio
20.3.15.3. Profitability by Market Segments (Product/Channel/Region)
20.3.15.4. Sales Footprint
20.3.15.5. Key Financials
20.3.15.6. SWOT Analysis
20.3.15.7. Strategy Overview
20.3.16. Advantagene Inc.,
20.3.16.1. Overview
20.3.16.2. Product Portfolio
20.3.16.3. Profitability by Market Segments (Product/Channel/Region)
20.3.16.4. Sales Footprint
20.3.16.5. Key Financials
20.3.16.6. SWOT Analysis
20.3.16.7. Strategy Overview
20.3.17. GenVec Inc.
20.3.17.1. Overview
20.3.17.2. Product Portfolio
20.3.17.3. Profitability by Market Segments (Product/Channel/Region)
20.3.17.4. Sales Footprint
20.3.17.5. Key Financials
20.3.17.6. SWOT Analysis
20.3.17.7. Strategy Overview
20.3.18. Glaxosmithkline PLC
20.3.18.1. Overview
20.3.18.2. Product Portfolio
20.3.18.3. Profitability by Market Segments (Product/Channel/Region)
20.3.18.4. Sales Footprint
20.3.18.5. Key Financials
20.3.18.6. SWOT Analysis
20.3.18.7. Strategy Overview
20.3.19. Amgen Inc.
20.3.19.1. Overview
20.3.19.2. Product Portfolio
20.3.19.3. Profitability by Market Segments (Product/Channel/Region)
20.3.19.4. Sales Footprint
20.3.19.5. Key Financials
20.3.19.6. SWOT Analysis
20.3.19.7. Strategy Overview
21. Assumptions and Acronyms Used22. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 01: Global Market Value (US$ Bn) Forecast by Region, 2017 & 2032
Table 02: Global Market Value (US$ Bn) Forecast by Therapy, 2017 & 2032
Table 03: Global Market Value (US$ Bn) Forecast by Indication, 2017 & 2032
Table 04: Global Market Value (US$ Bn) Forecast by Service Provider, 2017 & 2032
Table 05: North America Market Value (US$ Bn) Forecast by Country, 2017 & 2032
Table 06: North America Market Value (US$ Bn) Forecast by Therapy, 2017 & 2032
Table 07: North America Market Value (US$ Bn) Forecast by Indication, 2017 & 2032
Table 08: North America Market Value (US$ Bn) Forecast by Service Provider, 2017 & 2032
Table 09: Latin America Market Value (US$ Bn) Forecast by Country, 2017 & 2032
Table 10: Latin America Market Value (US$ Bn) Forecast by Therapy, 2017 & 2032
Table 11: Latin America Market Value (US$ Bn) Forecast by Indication, 2017 & 2032
Table 12: Latin America Market Value (US$ Bn) Forecast by Service Provider, 2017 & 2032
Table 13: Europe Market Value (US$ Bn) Forecast by Country, 2017 & 2032
Table 14: Europe Market Value (US$ Bn) Forecast by Therapy, 2017 & 2032
Table 15: Europe Market Value (US$ Bn) Forecast by Indication, 2017 & 2032
Table 16: Europe Market Value (US$ Bn) Forecast by Service Provider, 2017 & 2032
Table 17: East Asia Market Value (US$ Bn) Forecast by Country, 2017 & 2032
Table 18: East Asia Market Value (US$ Bn) Forecast by Therapy, 2017 & 2032
Table 19: East Asia Market Value (US$ Bn) Forecast by Indication, 2017 & 2032
Table 20: East Asia Market Value (US$ Bn) Forecast by Service Provider, 2017 & 2032
Table 21: South Asia Market Value (US$ Bn) Forecast by Country, 2017 & 2032
Table 22: South Asia Market Value (US$ Bn) Forecast by Therapy, 2017 & 2032
Table 23: South Asia Market Value (US$ Bn) Forecast by Indication, 2017 & 2032
Table 24: South Asia Market Value (US$ Bn) Forecast by Service Provider, 2017 & 2032
Table 25: Oceania Market Value (US$ Bn) Forecast by Country, 2017 & 2032
Table 26: Oceania Market Value (US$ Bn) Forecast by Therapy, 2017 & 2032
Table 27: Oceania Market Value (US$ Bn) Forecast by Indication, 2017 & 2032
Table 28: Oceania Market Value (US$ Bn) Forecast by Service Provider, 2017 & 2032
Table 29: MEA Market Value (US$ Bn) Forecast by Country, 2017 & 2032
Table 30: MEA Market Value (US$ Bn) Forecast by Therapy, 2017 & 2032
Table 31: MEA Market Value (US$ Bn) Forecast by Indication, 2017 & 2032
Table 32: MEA Market Value (US$ Bn) Forecast by Service Provider, 2017 & 2032
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 01: Global Market Value (US$ Bn) by Therapy, 2022 & 2032
Figure 02: Global Market Value (US$ Bn) by Indication, 2022 & 2032
Figure 03: Global Market Value (US$ Bn) by Service Provider, 2022 & 2032
Figure 04: Global Market Value (US$ Bn) by Region, 2022 & 2032
Figure 05: Global Market Value (US$ Bn) Analysis by Region, 2017 & 2032
Figure 06: Global Market Value Share (%) and BPS Analysis by Region, 2022 & 2032
Figure 07: Global Market Y-o-Y Growth (%) Projections by Region, 2022-2032
Figure 08: Global Market Value (US$ Bn) Analysis by Therapy, 2017 & 2032
Figure 09: Global Market Value Share (%) and BPS Analysis by Therapy, 2022 & 2032
Figure 10: Global Market Y-o-Y Growth (%) Projections by Therapy, 2022-2032
Figure 11: Global Market Value (US$ Bn) Analysis by Indication, 2017 & 2032
Figure 12: Global Market Value Share (%) and BPS Analysis by Indication, 2022 & 2032
Figure 13: Global Market Y-o-Y Growth (%) Projections by Indication, 2022-2032
Figure 14: Global Market Value (US$ Bn) Analysis by Service Provider, 2017 & 2032
Figure 15: Global Market Value Share (%) and BPS Analysis by Service Provider, 2022 & 2032
Figure 16: Global Market Y-o-Y Growth (%) Projections by Service Provider, 2022-2032
Figure 17: Global Market Attractiveness by Therapy, 2022-2032
Figure 18: Global Market Attractiveness by Indication, 2022-2032
Figure 19: Global Market Attractiveness by Service Provider, 2022-2032
Figure 20: Global Market Attractiveness by Region, 2022-2032
Figure 21: North America Market Value (US$ Bn) by Therapy, 2022 & 2032
Figure 22: North America Market Value (US$ Bn) by Indication, 2022 & 2032
Figure 23: North America Market Value (US$ Bn) by Service Provider, 2022 & 2032
Figure 24: North America Market Value (US$ Bn) by Country, 2022 & 2032
Figure 25: North America Market Value (US$ Bn) Analysis by Country, 2017 & 2032
Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2022 & 2032
Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 28: North America Market Value (US$ Bn) Analysis by Therapy, 2017 & 2032
Figure 29: North America Market Value Share (%) and BPS Analysis by Therapy, 2022 & 2032
Figure 30: North America Market Y-o-Y Growth (%) Projections by Therapy, 2022-2032
Figure 31: North America Market Value (US$ Bn) Analysis by Indication, 2017 & 2032
Figure 32: North America Market Value Share (%) and BPS Analysis by Indication, 2022 & 2032
Figure 33: North America Market Y-o-Y Growth (%) Projections by Indication, 2022-2032
Figure 34: North America Market Value (US$ Bn) Analysis by Service Provider, 2017 & 2032
Figure 35: North America Market Value Share (%) and BPS Analysis by Service Provider, 2022 & 2032
Figure 36: North America Market Y-o-Y Growth (%) Projections by Service Provider, 2022-2032
Figure 37: North America Market Attractiveness by Therapy, 2022-2032
Figure 38: North America Market Attractiveness by Indication, 2022-2032
Figure 39: North America Market Attractiveness by Service Provider, 2022-2032
Figure 40: North America Market Attractiveness by Country, 2022-2032
Figure 41: Latin America Market Value (US$ Bn) by Therapy, 2022 & 2032
Figure 42: Latin America Market Value (US$ Bn) by Indication, 2022 & 2032
Figure 43: Latin America Market Value (US$ Bn) by Service Provider, 2022 & 2032
Figure 44: Latin America Market Value (US$ Bn) by Country, 2022 & 2032
Figure 45: Latin America Market Value (US$ Bn) Analysis by Country, 2017 & 2032
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2022 & 2032
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 48: Latin America Market Value (US$ Bn) Analysis by Therapy, 2017 & 2032
Figure 49: Latin America Market Value Share (%) and BPS Analysis by Therapy, 2022 & 2032
Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Therapy, 2022-2032
Figure 51: Latin America Market Value (US$ Bn) Analysis by Indication, 2017 & 2032
Figure 52: Latin America Market Value Share (%) and BPS Analysis by Indication, 2022 & 2032
Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Indication, 2022-2032
Figure 54: Latin America Market Value (US$ Bn) Analysis by Service Provider, 2017 & 2032
Figure 55: Latin America Market Value Share (%) and BPS Analysis by Service Provider, 2022 & 2032
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Service Provider, 2022-2032
Figure 57: Latin America Market Attractiveness by Therapy, 2022-2032
Figure 58: Latin America Market Attractiveness by Indication, 2022-2032
Figure 59: Latin America Market Attractiveness by Service Provider, 2022-2032
Figure 60: Latin America Market Attractiveness by Country, 2022-2032
Figure 61: Europe Market Value (US$ Bn) by Therapy, 2022 & 2032
Figure 62: Europe Market Value (US$ Bn) by Indication, 2022 & 2032
Figure 63: Europe Market Value (US$ Bn) by Service Provider, 2022 & 2032
Figure 64: Europe Market Value (US$ Bn) by Country, 2022 & 2032
Figure 65: Europe Market Value (US$ Bn) Analysis by Country, 2017 & 2032
Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2022 & 2032
Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 68: Europe Market Value (US$ Bn) Analysis by Therapy, 2017 & 2032
Figure 69: Europe Market Value Share (%) and BPS Analysis by Therapy, 2022 & 2032
Figure 70: Europe Market Y-o-Y Growth (%) Projections by Therapy, 2022-2032
Figure 71: Europe Market Value (US$ Bn) Analysis by Indication, 2017 & 2032
Figure 72: Europe Market Value Share (%) and BPS Analysis by Indication, 2022 & 2032
Figure 73: Europe Market Y-o-Y Growth (%) Projections by Indication, 2022-2032
Figure 74: Europe Market Value (US$ Bn) Analysis by Service Provider, 2017 & 2032
Figure 75: Europe Market Value Share (%) and BPS Analysis by Service Provider, 2022 & 2032
Figure 76: Europe Market Y-o-Y Growth (%) Projections by Service Provider, 2022-2032
Figure 77: Europe Market Attractiveness by Therapy, 2022-2032
Figure 78: Europe Market Attractiveness by Indication, 2022-2032
Figure 79: Europe Market Attractiveness by Service Provider, 2022-2032
Figure 80: Europe Market Attractiveness by Country, 2022-2032
Figure 81: East Asia Market Value (US$ Bn) by Therapy, 2022 & 2032
Figure 82: East Asia Market Value (US$ Bn) by Indication, 2022 & 2032
Figure 83: East Asia Market Value (US$ Bn) by Service Provider, 2022 & 2032
Figure 84: East Asia Market Value (US$ Bn) by Country, 2022 & 2032
Figure 85: East Asia Market Value (US$ Bn) Analysis by Country, 2017 & 2032
Figure 86: East Asia Market Value Share (%) and BPS Analysis by Country, 2022 & 2032
Figure 87: East Asia Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 88: East Asia Market Value (US$ Bn) Analysis by Therapy, 2017 & 2032
Figure 89: East Asia Market Value Share (%) and BPS Analysis by Therapy, 2022 & 2032
Figure 90: East Asia Market Y-o-Y Growth (%) Projections by Therapy, 2022-2032
Figure 91: East Asia Market Value (US$ Bn) Analysis by Indication, 2017 & 2032
Figure 92: East Asia Market Value Share (%) and BPS Analysis by Indication, 2022 & 2032
Figure 93: East Asia Market Y-o-Y Growth (%) Projections by Indication, 2022-2032
Figure 94: East Asia Market Value (US$ Bn) Analysis by Service Provider, 2017 & 2032
Figure 95: East Asia Market Value Share (%) and BPS Analysis by Service Provider, 2022 & 2032
Figure 96: East Asia Market Y-o-Y Growth (%) Projections by Service Provider, 2022-2032
Figure 97: East Asia Market Attractiveness by Therapy, 2022-2032
Figure 98: East Asia Market Attractiveness by Indication, 2022-2032
Figure 99: East Asia Market Attractiveness by Service Provider, 2022-2032
Figure 100: East Asia Market Attractiveness by Country, 2022-2032
Figure 101: South Asia Market Value (US$ Bn) by Therapy, 2022 & 2032
Figure 102: South Asia Market Value (US$ Bn) by Indication, 2022 & 2032
Figure 103: South Asia Market Value (US$ Bn) by Service Provider, 2022 & 2032
Figure 104: South Asia Market Value (US$ Bn) by Country, 2022 & 2032
Figure 105: South Asia Market Value (US$ Bn) Analysis by Country, 2017 & 2032
Figure 106: South Asia Market Value Share (%) and BPS Analysis by Country, 2022 & 2032
Figure 107: South Asia Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 108: South Asia Market Value (US$ Bn) Analysis by Therapy, 2017 & 2032
Figure 109: South Asia Market Value Share (%) and BPS Analysis by Therapy, 2022 & 2032
Figure 110: South Asia Market Y-o-Y Growth (%) Projections by Therapy, 2022-2032
Figure 111: South Asia Market Value (US$ Bn) Analysis by Indication, 2017 & 2032
Figure 112: South Asia Market Value Share (%) and BPS Analysis by Indication, 2022 & 2032
Figure 113: South Asia Market Y-o-Y Growth (%) Projections by Indication, 2022-2032
Figure 114: South Asia Market Value (US$ Bn) Analysis by Service Provider, 2017 & 2032
Figure 115: South Asia Market Value Share (%) and BPS Analysis by Service Provider, 2022 & 2032
Figure 116: South Asia Market Y-o-Y Growth (%) Projections by Service Provider, 2022-2032
Figure 117: South Asia Market Attractiveness by Therapy, 2022-2032
Figure 118: South Asia Market Attractiveness by Indication, 2022-2032
Figure 119: South Asia Market Attractiveness by Service Provider, 2022-2032
Figure 120: South Asia Market Attractiveness by Country, 2022-2032
Figure 121: Oceania Market Value (US$ Bn) by Therapy, 2022 & 2032
Figure 122: Oceania Market Value (US$ Bn) by Indication, 2022 & 2032
Figure 123: Oceania Market Value (US$ Bn) by Service Provider, 2022 & 2032
Figure 124: Oceania Market Value (US$ Bn) by Country, 2022 & 2032
Figure 125: Oceania Market Value (US$ Bn) Analysis by Country, 2017 & 2032
Figure 126: Oceania Market Value Share (%) and BPS Analysis by Country, 2022 & 2032
Figure 127: Oceania Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 128: Oceania Market Value (US$ Bn) Analysis by Therapy, 2017 & 2032
Figure 129: Oceania Market Value Share (%) and BPS Analysis by Therapy, 2022 & 2032
Figure 130: Oceania Market Y-o-Y Growth (%) Projections by Therapy, 2022-2032
Figure 131: Oceania Market Value (US$ Bn) Analysis by Indication, 2017 & 2032
Figure 132: Oceania Market Value Share (%) and BPS Analysis by Indication, 2022 & 2032
Figure 133: Oceania Market Y-o-Y Growth (%) Projections by Indication, 2022-2032
Figure 134: Oceania Market Value (US$ Bn) Analysis by Service Provider, 2017 & 2032
Figure 135: Oceania Market Value Share (%) and BPS Analysis by Service Provider, 2022 & 2032
Figure 136: Oceania Market Y-o-Y Growth (%) Projections by Service Provider, 2022-2032
Figure 137: Oceania Market Attractiveness by Therapy, 2022-2032
Figure 138: Oceania Market Attractiveness by Indication, 2022-2032
Figure 139: Oceania Market Attractiveness by Service Provider, 2022-2032
Figure 140: Oceania Market Attractiveness by Country, 2022-2032
Figure 141: MEA Market Value (US$ Bn) by Therapy, 2022 & 2032
Figure 142: MEA Market Value (US$ Bn) by Indication, 2022 & 2032
Figure 143: MEA Market Value (US$ Bn) by Service Provider, 2022 & 2032
Figure 144: MEA Market Value (US$ Bn) by Country, 2022 & 2032
Figure 145: MEA Market Value (US$ Bn) Analysis by Country, 2017 & 2032
Figure 146: MEA Market Value Share (%) and BPS Analysis by Country, 2022 & 2032
Figure 147: MEA Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 148: MEA Market Value (US$ Bn) Analysis by Therapy, 2017 & 2032
Figure 149: MEA Market Value Share (%) and BPS Analysis by Therapy, 2022 & 2032
Figure 150: MEA Market Y-o-Y Growth (%) Projections by Therapy, 2022-2032
Figure 151: MEA Market Value (US$ Bn) Analysis by Indication, 2017 & 2032
Figure 152: MEA Market Value Share (%) and BPS Analysis by Indication, 2022 & 2032
Figure 153: MEA Market Y-o-Y Growth (%) Projections by Indication, 2022-2032
Figure 154: MEA Market Value (US$ Bn) Analysis by Service Provider, 2017 & 2032
Figure 155: MEA Market Value Share (%) and BPS Analysis by Service Provider, 2022 & 2032
Figure 156: MEA Market Y-o-Y Growth (%) Projections by Service Provider, 2022-2032
Figure 157: MEA Market Attractiveness by Therapy, 2022-2032
Figure 158: MEA Market Attractiveness by Indication, 2022-2032
Figure 159: MEA Market Attractiveness by Service Provider, 2022-2032
Figure 160: MEA Market Attractiveness by Country, 2022-2032
